Paragon Bioservices: Amicus advances its gene and cell therapies for rare metabolic diseases

On 3 July, Amicus Therapeutics and Paragon Bioservices (acquired by Catalent Biologics) entered into a manufacturing agreement to develop cell...Read More...The post Amicus advances its gene and cell therapies for rare metabolic diseases appeared first on Pharmaceutical Technology.